Dinitrochlorobenzene immunotherapy for verrucae resistant to standard treatment modalities - 07/10/17
Doi : 10.1016/S0190-9622(82)80199-0
W.G. Dunagin, M.D., L.E. Millikan, M.D. ⁎
From the University of Missouri and the Harry S Truman Veterans Administration Hospital.
aReprint requests to: Dr. L. E. Millikan, Tulane University School of Medicine, Section of Dermatology, 1430 Tulare Ave., New Orleans, LA 70112.
Résumé |
Using a different protocol from previous studies with dinitrochlorobenzene (DNCB), an 87% cure rate was achieved for difficult warts. All patients who entered in the study had failed to respond to prior conventional treatment modalities. Morbidity from the treatment was insignificant. We conclude that immunotherapy for warts is an important addition to current modalities, but we do not recommend its routine use or as initial treatment of ordinary warts.
Le texte complet de cet article est disponible en PDF.| Presented in part at the scientific meeting of the American Medical Association, St. Louis, MO, June 18, 1978. |
© 1982
Publié par Elsevier Masson SAS.
Vol 6 - N° 1
P. 40-45 - janvier 1982 Retour au numéro
Article précédent
- In situ demonstration of T cell subsets in atrophic parapsoriasis
- Euan M. McMillan, Rose Wasik, Mark Allen Everett
- Combined methotrexate-PUVA therapy in the treatment of psoriasis
- Warwick L. Morison, Khosrow Momtaz, John A. Parrish, Thomas B. Fitzpatrick
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?